Cancer Antibody Drug Conjugates Market, Drugs Approval, Price, Sales & Clinical Trials Insight to 2030 - ResearchAndMarkets.com

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Antibody drug conjugates (ADCs) have emerged as a transformative class of therapeutics in the cancer treatment landscape, integrating the specificity of monoclonal antibodies with the potency of cytotoxic drugs. These innovative therapies consist of an antibody linked to a cytotoxic agent through a stable linker, allowing targeted delivery to cancer cells while minimizing damage to surrounding healthy tissues.

The rapid evolution of antibody drug conjugates reflects their clinical and commercial success, with 16 products currently approved across various markets and sales surpassing US$ 10 Billion in 2023 and US$ 7 Billion in the first 6 months of 2024. This growth highlights antibody drug conjugates as a commercially viable segment of the broader cancer therapeutics market, prompting increased research and development efforts to create more effective and safer candidates.

Report Finding and Inclusions:

• Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
• Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
• Approved Cancer Antibody Drug Conjugates: 16 Drugs
• Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage & Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
• Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
• Insight On Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

Report Coverage:

• Mechanism of Action
• ADC Generations
• Pipeline & Approved Drugs Insight
• Sales Insight
• Current Trends
• Future Opportunities
• Market Drivers & Challenges

Drugs Covered:

• Enhertu
• Adcetris
• Polivy
• Kadcyla
• Others

Companies Covered:

• Biocytogen
• Merck
• AstraZeneca
• Pfizer
• Daiichi Sankyo
• ADC Therapeutics

As of October 2024, regulatory authorities around the world have approved 16 antibody drug conjugates, with 13 currently available for clinical use for different cancer types. Among these, prominent examples include Padcev, Kadcyla, and Enhertu, which collectively accounted for approximately 60% of the total antibody drug conjugates sales in 2023. While Enhertu is indicated for the treatment of several HER2-positive solid cancers, Padcev and Kadcyla are solely approved for the treatment of bladder cancer and breast cancer, respectively. The commercialization of these products demonstrates not only their therapeutic potential but also the market's growing confidence in the effectiveness of ADCs in managing various cancer types.

The global cancer antibody drug conjugates market is characterized by a competitive landscape, with substantial development efforts targeting multiple cancers, including both solid tumors and hematological malignancies. However, out of all these, lung cancer is currently witnessing the most extensive development activity, with over 60 candidates in clinical trials, including CAB-AXL-ADC, TQB2102, and MYTX-011, and one Enhertu, approved for use in clinical setting. This reflects a strategic shift towards addressing the high-unmet medical need in lung cancer, which remains one of the leading causes of cancer mortality worldwide. The potential for antibody drug conjugates to provide more effective and less toxic treatment options makes them particularly attractive in this therapeutic area.

In contrast, however, breast cancer has experienced the highest number of antibody drug conjugates approvals to date, with four approved candidates, contributing significantly to the market's commercial success. Two key players in this domain are the aforementioned Kadcyla and Enhertu, both of which have demonstrated remarkable efficacy and have achieved significant sales milestones. The promising pipeline also includes AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan, a TROP2-directed antibody drug conjugate that is currently under review for its use in breast cancer treatment. This continued investment in research and development underscores the critical role antibody drug conjugates play in advancing cancer care.

Regionally, the cancer antibody drug conjugates market is primarily led by the US and China, two of the largest and most dynamic pharmaceutical markets globally. In the US, robust healthcare infrastructure, high R&D expenditure, and a favorable regulatory environment foster innovation and accelerate the approval process for new therapies. Additionally, the presence of major pharmaceutical companies, such as Regeneron, Gilead, Merck and Pfizer, bolsters the competitive landscape, enabling rapid development and commercialization of antibody drug conjugates.

In China, the growing demand for advanced cancer treatments, coupled with increasing government support for biotechnology and pharmaceutical research, has catalyzed significant growth in the antibody drug conjugates sector. Local players like Mabwell, Miracogen, Chia Tai Tianqing Pharmaceutical, Hansoh BioMedical, Sichuan Baili Pharmaceuticals, Biocytogen and Affinity Biopharma are emerging as significant contributors to the market, developing novel Antibody drug conjugates tailored to the specific needs of the Chinese patient population, and out licensing promising candidates to their international counterparts through license agreements.

The global market for cancer antibody drug conjugates represents a dynamic and rapidly evolving segment of the cancer therapeutics landscape. With ongoing clinical trials, innovative research, and increasing regulatory support, antibody drug conjugates are poised to play an increasingly pivotal role in cancer treatment. As efforts continue to address existing challenges and expand the range of approved indications, the future of antibody drug conjugates appears promising, offering hope to patients worldwide in the fight against cancer. The collaborative efforts among pharmaceutical companies, regulatory bodies, and research institutions will be crucial in shaping the next wave of advancements in this exciting therapeutic field.

Key Topics Covered:

1. Introduction To Antibody Drug Conjugates

2. Antibody Drug Conjugates As Cancer Targeted Therapy

• Applications of Antibody Drug Conjugates in Cancer
• Advantages of Antibody Drug Conjugates
• Comparison of Antibody Drug Conjugates With Traditional Therapies

3. Generations of Antibody Drug Conjugates

• Antibody Drug Conjugates - Evolution
• Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

5. Global Cancer Antibody Drug Conjugates Clinical Trials Overview

• By Phase
• By Indication
• By Company
• By Patient Segment
• By Country

6. Global Cancer Antibody Drug Conjugates Market Outlook

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

• Lung Cancer
• Breast cancer
• Leukemia
• Ovarian Cancer
• Gastrointestinal Cancer
• Lymphoma
• Urogenital Cancer
• Cervical Cancer
• Head & Neck Cancer
• Brain Cancer
• Prostate cancer
• Pancreatic Cancer
• Skin cancer
• Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

• Mylotarg
• Adcetris
• Kadcyla
• Besponsa
• Lumoxiti (Market Withdrawal In 2023)
• Polivy
• Padcev
• Enhertu
• Trodelvy
• Blenrep (Partial Market Withdrawal In 2023)
• Zynlonta
• Tivdak
• Elahere
• Ujvira
• Akalux
• Aidixi

11. Approved Cancer Antibody Drug Conjugates - Sales Insights & Forecast 2028

• Adcetris
• Padcev
• Tivdak
• Polivy
• Kadcyla
• Besponsa
• Enhertu
• Trodelvy
• Zynlonta
• Elahere
• Blenrep

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

• Research
• Preclinical
• Phase I
• Phase I/II
• Phase II
• Phase II/III
• Phase III
• Preregistration

13. Marketed Cancer Antibody Drug Conjugates Clinical Insight By Company, Country & Indication

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

16. Competitive Landscape

• Biocytogen
• Bristol Myers Squibb
• Eli Lilly
• Innovent Biologics
• Merck
• Pfizer
• Affinity Biopharma
• Biokin
• Synaffix
• ADC Therapeutics
• AstraZeneca
• Daiichi Sankyo
• Duality Biologics
• Immunogen
• LigaChem Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/z4bxyp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241106127381/en/